| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 10/28/2004 | WO2003030833A3 Angiopoietin-2 specific binding agents |
| 10/28/2004 | WO2003026591A3 Modification of feeding behavior |
| 10/28/2004 | WO2003018515A3 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 10/28/2004 | US20040215014 Auroyl cyclic amines for controlling behavior or appetite |
| 10/28/2004 | US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders |
| 10/28/2004 | US20040214901 derivatives which inhibit pancreatic lipase and therefore can be used in combating or preventing obesity and hyperlipaemias |
| 10/28/2004 | US20040214896 drugs and/or prodrugs such as N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide, used for prophylaxis of inflammatory disorders, cancers, psoriasis, diabetes, autoimmune diseases, hepatitis, graft versus host disease or endometriosis |
| 10/28/2004 | US20040214894 adminstering to a patient for suppressing, ameliorating, or treating methionine-induced anemia a threonine or salts; side effect reduction |
| 10/28/2004 | US20040214888 Carboxylic acid derivative and medicine comprising salt or ester of the same |
| 10/28/2004 | US20040214887 for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy |
| 10/28/2004 | US20040214875 Imidazolinylmethyl aralkylsulfonamides |
| 10/28/2004 | US20040214868 Treatment or prevention of type 2 diabetes; chemical synthesis; 2-[ benzoyl]aminopyridine-5-carboxylate derivatives |
| 10/28/2004 | US20040214866 Antidiabetic agents; dietetics; hypoglycermic agents; stable, high melting crystalline material, suitable for bulk preparation and handling |
| 10/28/2004 | US20040214864 Novel compounds |
| 10/28/2004 | US20040214856 Cannabinoid receptor ligands and uses thereof |
| 10/28/2004 | US20040214855 Cannabinoid receptor ligands and uses thereof |
| 10/28/2004 | US20040214853 Analgesics; side effect reduction; antidiabetic agents; central nervous system disorders |
| 10/28/2004 | US20040214839 administering prostaglandin or agonist thereof and type IV selective phosphodiesterase (PDE) inhibitor to induce tolerance to antigens |
| 10/28/2004 | US20040214838 such as 6-benzyl-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2,6-dihydropyrazolo[3,4-c]pyridin-7-one; for treatment of eating disorders and psychological disorders |
| 10/28/2004 | US20040214837 such as 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-(4-methylpiperazin-1-yl)-2H-pyrazolo[4,3-d]pyrimidine; for treatment of eating disorders and psychological disorders |
| 10/28/2004 | US20040214822 Substituted 4-aminocyclohexanol compounds |
| 10/28/2004 | US20040214820 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 10/28/2004 | US20040214815 Therapeutic compounds |
| 10/28/2004 | US20040214814 Pyrazole compounds useful as protein kinase inhibitors |
| 10/28/2004 | US20040214803 1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor vitamin D3; for preventing and/or treating allograft rejection |
| 10/28/2004 | US20040214759 Compositions and methods of use for a fibroblast growth factor |
| 10/28/2004 | US20040214321 Agent for inducing conversion of intestinal cells into insulin-producing cells and antidiabetic drug |
| 10/28/2004 | US20040214286 Comprises nucleotide sequences coding cell growth factors for use in developing modulators for treatment of cell proliferative, arthritic, skin and vision defects; immunotherapy |
| 10/28/2004 | US20040214270 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fattly liver in lipid biosynthesis |
| 10/28/2004 | US20040214264 Comprises nucleotide sequences coding dimethylarginine dimethylaminohydrolase-1 protein (DDAH1) for use in identifying modulators for treatment of diabetes and cardiovascular disorders |
| 10/28/2004 | US20040214261 culturing genetically modified microorganism containing polyglutamyl hydrolase (from rodents, mammals, or humans) activity to enhance generation of monoglutamyl folate; food processing; dairy products |
| 10/28/2004 | US20040214234 Method |
| 10/28/2004 | US20040214188 Diagnosis and treatment of diabetic , muscle, metabolic and eating disorders |
| 10/28/2004 | US20040213797 Conjugates for the modulation of immune responses |
| 10/28/2004 | US20040213787 Vascular Endothelial Growth Factors (VEGF) by injection; for decreased serum glucose concentrations, improved glucose tolerance, increased insulin sensitivity, and reduced hyperinsulinemia |
| 10/28/2004 | US20040213769 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 10/28/2004 | US20040213442 Novel fatty acids analogous |
| 10/28/2004 | DE10043937B4 Herstellung einer dreiwertigen Chromkomplexverbindung und eines selbige enthaltenden Milchprodukts Producing a trivalent chromium complex compound and a selbige containing milk product |
| 10/28/2004 | CA2526899A1 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 10/28/2004 | CA2522322A1 Agent for treating diabetes mellitus |
| 10/28/2004 | CA2522266A1 Phenylazole compound, production process therefor and antioxidant |
| 10/28/2004 | CA2522126A1 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes |
| 10/28/2004 | CA2522118A1 Compounds that modulate ppar activity and methods of preparation |
| 10/28/2004 | CA2522080A1 N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
| 10/28/2004 | CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling |
| 10/28/2004 | CA2521832A1 Heterocyclic mchr1 antagonists |
| 10/28/2004 | CA2521175A1 Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| 10/28/2004 | CA2521135A1 N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders |
| 10/27/2004 | EP1471152A1 Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| 10/27/2004 | EP1471064A1 Coumarin derivatives, process for their production and use thereof |
| 10/27/2004 | EP1471055A1 6-phenylpyridyl-2-amine derivatives |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1471049A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470246A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 10/27/2004 | EP1470144A2 Oligonucleotides comprising alternating segments and uses thereof |
| 10/27/2004 | EP1470137A1 Edg receptor agonists |
| 10/27/2004 | EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| 10/27/2004 | EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |
| 10/27/2004 | EP1470102A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
| 10/27/2004 | EP1469889A2 Ex-vivo gene therapy of diabetes using iap polypeptides |
| 10/27/2004 | EP1469887A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 10/27/2004 | EP1469875A1 Compositions and methods for modulating connexin hemichannels |
| 10/27/2004 | EP1469874A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 10/27/2004 | EP1469873A2 Peptidomimetic inhibitors of post-proline cleaving enzymes |
| 10/27/2004 | EP1469862A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 10/27/2004 | EP1469860A2 Anti-cancer combination and use thereof |
| 10/27/2004 | EP1469857A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis |
| 10/27/2004 | EP1469856A2 8-heteroaryl xanthine adenosine a sb 2b /sb receptor antagonists |
| 10/27/2004 | EP1469854A1 Condensed heterocyclic compounds |
| 10/27/2004 | EP1469851A1 Melanocortin receptor agonists |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1469843A1 Composition for pharmaceutical or dietetic use for combating hair loss |
| 10/27/2004 | EP1469842A2 Bicyclic cb2 cannabinoid receptor ligands |
| 10/27/2004 | EP1469838A1 Manufacture of oral dosage forms delivering both immediate release and sustained release drugs |
| 10/27/2004 | EP1469835A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 10/27/2004 | EP1469834A1 Multi-stage oral drug controlled-release system |
| 10/27/2004 | EP1469830A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 10/27/2004 | EP1469827A2 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 10/27/2004 | EP1469812A2 Oral insulin therapy |
| 10/27/2004 | EP1469741A1 A process for the extraction,purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent |
| 10/27/2004 | EP1373263B1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 10/27/2004 | EP1244457B1 Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases |
| 10/27/2004 | EP1242418B1 Antidiabetic thiazolidinediones and their preparation |
| 10/27/2004 | EP1237578A4 Micro-cluster liquids and methods of making and using them |
| 10/27/2004 | EP1150574B1 A natural tea for curing men's impotence and a method for manufacturing the same |
| 10/27/2004 | EP1107793B1 Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| 10/27/2004 | EP0914091B9 Ethene containing solutions and use thereof in methods of therapy or prophylaxis |
| 10/27/2004 | EP0813544B1 Bradykinin antagonist peptides incorporating n-substituted glycines |
| 10/27/2004 | CN1541265A Identification of DNA variant associated with adult type hypolactasia |
| 10/27/2004 | CN1541211A Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same |
| 10/27/2004 | CN1541210A Arylsulfonyl derivatives with 5-HT6 receptor affinity |
| 10/27/2004 | CN1541102A Somatostain agonists |
| 10/27/2004 | CN1541094A Treatment of lipodystrophy |
| 10/27/2004 | CN1541092A Method for treating primary insomnia |
| 10/27/2004 | CN1539849A Polypeptides encoded by haman lipase-like gene and compsns, and metods of utilizing same |
| 10/27/2004 | CN1539844A 2,3,5,4'-tetrahydroxy diphenyl ethylene-2-1-beta-D-glucoside |
| 10/27/2004 | CN1539475A Combination of natural products for curing hyperlipemia, atherosclerosis and relevant disease |
| 10/27/2004 | CN1539429A Deoxyadenosine in aplication of preparing bypolipidemic |